{"id":58443,"date":"2026-02-28T14:11:28","date_gmt":"2026-02-28T06:11:28","guid":{"rendered":"https:\/\/flcube.com\/?p=58443"},"modified":"2026-02-28T14:11:29","modified_gmt":"2026-02-28T06:11:29","slug":"asieris-apl-1702-maa-accepted-by-ema-first-photodynamic-therapy-for-cervical-hsil-nears-eu-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58443","title":{"rendered":"Asieris&#8217; APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval"},"content":{"rendered":"\n<p><strong>Asieris Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/688176:SHA\">SHA:\u202f688176<\/a>)<\/strong> announced that the <strong>European Medicines Agency (EMA)<\/strong> has accepted the <strong>Marketing Authorization Application (MAA)<\/strong> for <strong>APL-1702 (CEVIRA)<\/strong>, a <strong>world\u2011first photodynamic therapy (PDT)<\/strong> for the treatment of <strong>cervical high\u2011grade squamous intraepithelial lesions (HSIL)<\/strong>. The innovative product combines <strong>hexyl aminolevulinate hydrochloride ointment<\/strong> with a <strong>single\u2011use intravaginal cold light source<\/strong>, offering a <strong>non\u2011surgical alternative<\/strong> to conventional excisional procedures.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Asieris Pharmaceuticals (SHA:\u202f688176)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>APL-1702 (CEVIRA)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Photodynamic therapy (PDT) \u2013 world\u2011first for cervical HSIL<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>EMA MAA accepted<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cervical high\u2011grade squamous intraepithelial lesions (HSIL)<\/td><\/tr><tr><td><strong>Components<\/strong><\/td><td>Hexyl aminolevulinate HCl ointment + single\u2011use cervical PDT lamp<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>Local drug delivery + intravaginal cold light source<\/td><\/tr><tr><td><strong>Prior Submission<\/strong><\/td><td>NMPA NDA submitted May\u202f2024 (China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-international-phase-iii\">Clinical Evidence \u2013 International Phase III<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Design<\/strong><\/td><td>International multi\u2011center Phase III<\/td><\/tr><tr><td><strong>European Participation<\/strong><\/td><td>&gt;\u202f20% of participants enrolled from Europe<\/td><\/tr><tr><td><strong>Primary Support<\/strong><\/td><td>EMA MAA based on Phase III data<\/td><\/tr><tr><td><strong>Treatment Modality<\/strong><\/td><td>Non\u2011surgical PDT vs. conventional excision (LEEP\/cone biopsy)<\/td><\/tr><tr><td><strong>Clinical Value<\/strong><\/td><td>Cervical\u2011sparing alternative for women of childbearing age<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cervical HSIL Unmet Need:<\/strong> HSIL (CIN\u202f2\/3) affects <strong>millions of women globally<\/strong>; standard <strong>LEEP\/cone biopsy<\/strong> carries <strong>cervical incompetence risks<\/strong> affecting future pregnancy outcomes\u2014APL-1702 offers <strong>fertility\u2011preserving alternative<\/strong>.<\/li>\n\n\n\n<li><strong>Photodynamic Innovation:<\/strong> As the <strong>world\u2011first PDT for cervical HSIL<\/strong>, APL-1702 establishes a <strong>new therapeutic class<\/strong>, potentially expanding to other HPV\u2011related precancerous conditions (vulvar, anal HSIL).<\/li>\n\n\n\n<li><strong>Dual Regulatory Strategy:<\/strong> <strong>NMPA NDA (May\u202f2024)<\/strong> + <strong>EMA MAA (Feb\u202f2026)<\/strong> demonstrates Asieris&#8217; <strong>global ambitions<\/strong> and <strong>China\u2011first innovation model<\/strong> with international validation.<\/li>\n\n\n\n<li><strong>European Market Access:<\/strong> EMA acceptance positions APL-1702 for <strong>EU\u2011wide approval<\/strong>, addressing significant demand for <strong>non\u2011invasive cervical disease management<\/strong> in European screening programs.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Cervical HSIL Incidence<\/strong><\/td><td>~\u202f500,000+ cases annually in EU; current standard of care invasive with fertility concerns<\/td><\/tr><tr><td><strong>PDT Market Expansion<\/strong><\/td><td>Photodynamic therapy established in dermatology\/oncology; cervical application represents novel expansion<\/td><\/tr><tr><td><strong>Asieris Differentiation<\/strong><\/td><td>First\u2011mover in cervical PDT; potential for orphan\u2011like positioning given lack of alternatives<\/td><\/tr><tr><td><strong>Reimbursement Pathway<\/strong><\/td><td>Non\u2011surgical approach may qualify for premium pricing vs. LEEP; cost\u2011effectiveness data critical for NICE\/EMA assessment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding EMA review timelines, approval expectations, and global commercialization potential for APL-1702. Actual results may differ due to risks including regulatory review outcomes, manufacturing scalability for device\u2011drug combination, and physician adoption of non\u2011surgical HSIL management.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/688176_20260228_HLXH.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688176_20260228_HLXH.\"><\/object><a id=\"wp-block-file--media-a855ff9c-209f-49bd-8653-861a1a1c9054\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/688176_20260228_HLXH.pdf\">688176_20260228_HLXH<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/688176_20260228_HLXH.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a855ff9c-209f-49bd-8653-861a1a1c9054\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Asieris Pharmaceuticals (SHA:\u202f688176) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[316,38,25,1127],"class_list":["post-58443","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-asieris-pharmaceuticals","tag-market-approval-filings","tag-potential-first-in-class","tag-sha-688176"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Asieris&#039; APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Asieris Pharmaceuticals (SHA:\u202f688176) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for APL-1702 (CEVIRA), a world\u2011first photodynamic therapy (PDT) for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL). The innovative product combines hexyl aminolevulinate hydrochloride ointment with a single\u2011use intravaginal cold light source, offering a non\u2011surgical alternative to conventional excisional procedures.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58443\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asieris&#039; APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval\" \/>\n<meta property=\"og:description\" content=\"Asieris Pharmaceuticals (SHA:\u202f688176) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for APL-1702 (CEVIRA), a world\u2011first photodynamic therapy (PDT) for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL). The innovative product combines hexyl aminolevulinate hydrochloride ointment with a single\u2011use intravaginal cold light source, offering a non\u2011surgical alternative to conventional excisional procedures.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58443\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-28T06:11:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-28T06:11:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58443#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58443\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Asieris&#8217; APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval\",\"datePublished\":\"2026-02-28T06:11:28+00:00\",\"dateModified\":\"2026-02-28T06:11:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58443\"},\"wordCount\":411,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Asieris Pharmaceuticals\",\"Market approval filings\",\"Potential first-in-class\",\"SHA: 688176\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58443#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58443\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58443\",\"name\":\"Asieris' APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-28T06:11:28+00:00\",\"dateModified\":\"2026-02-28T06:11:29+00:00\",\"description\":\"Asieris Pharmaceuticals (SHA:\u202f688176) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for APL-1702 (CEVIRA), a world\u2011first photodynamic therapy (PDT) for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL). The innovative product combines hexyl aminolevulinate hydrochloride ointment with a single\u2011use intravaginal cold light source, offering a non\u2011surgical alternative to conventional excisional procedures.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58443#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58443\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58443#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Asieris&#8217; APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Asieris' APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Asieris Pharmaceuticals (SHA:\u202f688176) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for APL-1702 (CEVIRA), a world\u2011first photodynamic therapy (PDT) for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL). The innovative product combines hexyl aminolevulinate hydrochloride ointment with a single\u2011use intravaginal cold light source, offering a non\u2011surgical alternative to conventional excisional procedures.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58443","og_locale":"en_US","og_type":"article","og_title":"Asieris' APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval","og_description":"Asieris Pharmaceuticals (SHA:\u202f688176) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for APL-1702 (CEVIRA), a world\u2011first photodynamic therapy (PDT) for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL). The innovative product combines hexyl aminolevulinate hydrochloride ointment with a single\u2011use intravaginal cold light source, offering a non\u2011surgical alternative to conventional excisional procedures.","og_url":"https:\/\/flcube.com\/?p=58443","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-28T06:11:28+00:00","article_modified_time":"2026-02-28T06:11:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58443#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58443"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Asieris&#8217; APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval","datePublished":"2026-02-28T06:11:28+00:00","dateModified":"2026-02-28T06:11:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58443"},"wordCount":411,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Asieris Pharmaceuticals","Market approval filings","Potential first-in-class","SHA: 688176"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58443#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58443","url":"https:\/\/flcube.com\/?p=58443","name":"Asieris' APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-28T06:11:28+00:00","dateModified":"2026-02-28T06:11:29+00:00","description":"Asieris Pharmaceuticals (SHA:\u202f688176) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for APL-1702 (CEVIRA), a world\u2011first photodynamic therapy (PDT) for the treatment of cervical high\u2011grade squamous intraepithelial lesions (HSIL). The innovative product combines hexyl aminolevulinate hydrochloride ointment with a single\u2011use intravaginal cold light source, offering a non\u2011surgical alternative to conventional excisional procedures.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58443#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58443"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58443#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Asieris&#8217; APL-1702 MAA Accepted by EMA \u2013 First Photodynamic Therapy for Cervical HSIL Nears EU Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58443"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58443\/revisions"}],"predecessor-version":[{"id":58445,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58443\/revisions\/58445"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}